This increased secretion in response to PBA treatment in vivo is supported by data from other matrix diseases including Pierson syndrome due to laminin B2 mutations (29) and Osteogenesis Imperfecta caused by a Col1a1 mutation (45). Here, COL1A1 is linked to osteogenesis imperfecta.